EDGEWISE THERAPEUTICS INC (EWTX)
NASDAQ • Healthcare
$44.11
+$0.07 (+0.2%)
Market open
Last close at August 18, 2026 at 20:00 UTC
Fundamentals Charts
About EDGEWISE THERAPEUTICS INC
Name
EDGEWISE THERAPEUTICS INC
CEO
Kevin Koch
Website
Industry
Healthcare
Year Founded
2017
Employees
127
Edgewise Therapeutics, Inc. is a NASDAQ-listed biotechnology company focused on small-molecule medicines for muscle disease. In qualitative terms, it is an early-stage healthcare developer, and its lead program is EDG-5506, an orally administered compound being studied for dystrophinopathies and other genetically defined muscle conditions.
Fundamentals & Financials
Revenue (TTM)
$0
Net Income (TTM)
-$197.2M
EPS (TTM)
-$1.85
ROA (TTM)
-41.11%
Current Ratio
16.24
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings Calendar
Stay Ahead of the Market
Get premium market insights delivered directly to your inbox.
Quote Summary
Previous CloseDay Range$44.11$42.62 - $45.29
52 Week RangeAvg. Volume$13.53 - $48.41.1M
Market Cap$4.8B
Peers & Related Assets
CLDXCELLDEX THERAPEUTICS INC
$41.79-0.3%
NUVBNUVATION BIO INC CLASS A
$6.96+7.4%
VERAVERA THERAPEUTICS INC CLASS A
$32.28+2.1%
QUREuniQure N.V.
GPCRStructure Therapeutics Inc.
VRDNVIRIDIAN THERAPEUTICS ORS INC
OCULOCULAR THERAPEUTIX INC
MESOMesoblast Limited
GLPGGalapagos N.V.
JANXJANUX THERAPEUTICS INC